Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. is terminating the public listing of its subsidiary, Liaoning Kangda Color Printing Packaging Co., Ltd.'s assets due to a lack of interested buyers after one year of offering the assets for sale [1][2]. Group 1: Asset Disposal Decision - On August 28, 2024, the company's board approved the public listing of certain assets from Liaoning Kangda Color Printing Packaging Co., Ltd. to enhance operational quality and profitability [1]. - The assets include 24,763.11 square meters of buildings, 46,872.11 square meters of land use rights, and 12 structures, with an assessed value of 37.35 million yuan [1]. Group 2: Asset Listing Progress - From October 12, 2024, to October 12, 2025, the assets were publicly listed on the Shenyang United Property Rights Exchange, but no interested buyers were found by the deadline [2]. - On October 13, 2025, the company received a confirmation from the exchange regarding the lack of interest in the assets, leading to the termination of the listing [2].

Core Viewpoint - Nanjing Pharmaceutical announced a significant reduction in its convertible bonds by its controlling shareholder, indicating a strategic shift in investment or liquidity management [1] Group 1: Company Actions - The controlling shareholder, Nanjing New Industry Investment Group Co., Ltd., notified that it has reduced its holdings of "Nanjing Pharmaceutical Convertible Bonds" by 1,108,000 units [1] - This reduction represents 10.25% of the total issuance of the convertible bonds [1]

一、控股股东配售可转债情况 经中国证券监督管理委员会《关于同意南京医药股份有限公司向不特定对象发 行可转换公司债券注册的批复》（证监许可〔2024〕1736 号）核准，公司向不特 定对象发行可转债 10,814,910 张，每张面值为人民币 100 元（人民币，下同），发 行总额 108,149.10 万元。本次发行的可转债存续期限为自发行之日起六年（2024 年 12 月 25 日至 2030 年 12 月 24 日）。 证券代码：600713 证券简称：南京医药 编号：ls2025-129 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于控股股东减持公司可转换公司债券的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）于近日收到控股股东南京新工投 资集团有限责任公司（以下简称"新工投资集团"）的通知，新工投资集团已于 2025 年 9 月 16 日至 2025 年 10 月 14 日期间通过上海证券交易所（以下简称"上交 所"）系统减持其持有的部分公司可 ...

Group 1 - The company Nanjing Pharmaceutical (600713.SH) has received a notification from New Investment Group regarding a reduction in holdings [1] - The reduction period for the convertible bonds occurred from September 16, 2025, to October 14, 2025 [1] - New Investment Group has cumulatively reduced its holdings of "Nanjing Pharmaceutical Convertible Bonds" by 1.108 million units, which accounts for 10.25% of the total issuance of the convertible bonds [1]

Core Points - New Industrial Investment Group plans to reduce its holdings of "Nanjing Pharmaceutical Convertible Bonds" by 1.108 million units from September 16 to October 14, 2025, which accounts for 10.25% of the total issuance [1] - After the reduction, the group will hold 2.5807 million units, representing 23.86% of the total [1] - Previously, the group had already reduced its holdings by 1.0815 million units from September 1 to September 15, 2025, which accounted for 10.00% of the total [1]

Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. announced the termination of the public listing for the disposal of assets from its wholly-owned subsidiary, Liaoning Kangda Color Printing and Packaging Co., Ltd., due to the lack of interested buyers after one year of open bidding [1][2]. Group 1: Asset Disposal Decision - On August 28, 2024, the company's board approved the public listing for the disposal of certain assets, including land use rights and buildings, with a minimum listing price based on an asset evaluation of 37.35 million yuan [1]. - The assets include 24,763.11 square meters of buildings, 46,872.11 square meters of land use rights, and 12 structures, all located in Shenyang Economic and Technological Development Zone [1]. Group 2: Asset Listing Progress - From October 12, 2024, to October 12, 2025, the assets were publicly listed on the Shenyang United Property Rights Exchange, but no interested buyers were found by the deadline [2]. - On October 13, 2025, the company received a confirmation letter from the exchange stating that the asset listing had ended without any bids [2].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为盘活内部闲置资产，进一步聚焦核心资源提升公司整体运营质量和盈利水平， 南京医药股份有限公司（以下简称"公司"）全资子公司辽宁康大彩印包装有限公 司（以下简称"康大彩印"）公开挂牌处置其拥有的部分土地使用权及房屋建筑物 等。截止2025年10月12日，仍未征集到意向受让方，本次挂牌自行终止。现将具体 情况公告如下： 证券代码：600713 证券简称：南京医药 编号：ls2025-128 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于全资子公司辽宁康大彩印包装有限公司公开挂牌 处置相关资产的进展公告 三、风险提示 公司将根据该事项具体情况另行确定资产处置方案并及时履行信息披露义务。 敬请广大投资者注意投资风险。 特此公告 南京医药股份有限公司董事会 2025 年 10 月 15 日 1 一、康大彩印资产挂牌决策情况 2024年8月28日，公司第九届董事会第八次会议审议通过《关于拟公开挂牌处 置辽宁康大彩印包装有限公司相关资产的议案》。董事会同意康大彩印以不低 ...

| | | 南京医药股份有限公司关于公司及子公司 使用部分暂时闲置募集资金进行现金管理到期赎回并继续 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理产品名称：南京医药股份有限公司（以下简称"公司"）子公 司福建同春药业股份有限公司（以下简称"福建同春"）本次使用部分暂时闲置 募集资金 6,000 万元购买招商银行单位大额存单 2025 年第 3229 期。 履行的审议程序：公司于2025年1月20-22日召开了第九届董事会临时会 议及第九届监事会临时会议，审议通过了《关于公司及子公司使用部分暂时闲置 募集资金进行现金管理的议案》，同意公司及子公司使用不超过7亿元（含本数） 暂时闲置募集资金进行现金管理，投资的产品品种为安全性较高、流动性较好、 风险较低的保本型理财产品。使用期限自公司董事会审议通过之日起12个月内有 效，上述额度在使用期限内可以滚动使用，到期后归还至募集资金专户。 特别风险提示：尽管公司购买的单位大额存单安全性较高、流动性较好、 风险较低，但金融市场受宏观经济的影响 ...

债券代码：110098 债券简称：南药转债 南京医药股份有限公司关于公司及子公司 使用部分暂时闲置募集资金进行现金管理提前赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）于 2025 年 1 月 20-22 日召开 第九届董事会临时会议及第九届监事会临时会议，审议通过了《关于公司及子公 司使用部分暂时闲置募集资金进行现金管理的议案》，同意公司及子公司使用不 超过 7 亿元（含本数）暂时闲置募集资金进行现金管理，投资的产品品种为安全 性较高、流动性较好、风险较低的保本型理财产品。使用期限自公司董事会审议 通过之日起 12 个月内有效，上述额度在使用期限内可以滚动使用，到期后归还 至募集资金专户。详情请见公司于2025年1月23日对外披露的编号为ls2025-007 之《南京医药股份有限公司关于公司及子公司使用部分暂时闲置募集资金进行现 金管理的公告》。 | | | 1 公司于 2025 年 6 月 24 日赎回部分上述理财产品，收回本金 200 万元，并获 得理财收益 0.00 ...

Core Viewpoint - Nanjing Pharmaceutical has announced the progress of its share repurchase plan, which aims to utilize self-owned or raised funds to buy back shares for the implementation of its 2025 restricted stock incentive plan [2][3]. Summary by Sections Repurchase Plan Overview - On March 14, 2025, Nanjing Pharmaceutical's board approved a share repurchase plan, with the first disclosure on March 15, 2025. The repurchase period is set from March 14, 2025, to March 14, 2026. The expected repurchase amount is between 70 million yuan (approximately 10.1 million USD) and 131.58 million yuan (approximately 18.8 million USD), with a maximum repurchase price of 7.31 yuan (approximately 1.05 USD) per share [2]. Repurchase Progress Details - As of the announcement date, the company has repurchased a total of 16,299,951 shares, accounting for 1.25% of the total share capital, with a cumulative repurchase amount of 80.2576 million yuan (approximately 11.5 million USD). The actual repurchase price ranged from 4.69 yuan (approximately 0.67 USD) to 5.22 yuan (approximately 0.75 USD) per share. The total share capital increased from 1,308,928,704 shares at the end of August 2025 to 1,308,929,289 shares at the end of September 2025 due to the conversion of convertible bonds [3]. Future Plans - Nanjing Pharmaceutical will adhere to relevant regulations and guidelines during the repurchase period and will make repurchase decisions based on market conditions while fulfilling its information disclosure obligations in a timely manner [4].